BioCentury
ARTICLE | Company News

Nuclea, IRCM deal

September 28, 2015 7:00 AM UTC

Nuclea and the IRCM plan to develop quantitative mass spectrometry-based assays to determine the progression and risk of Type II diabetes. The partners will validate the assays for insulin, proinsulin...